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Background. This open-label single-arm exploratory study evaluated the accuracy of the Ingestible Sensor System
(ISS), a novel technology for directly assessing the ingestion of oral medications and treatment adherence.
Methods. ISS consists of an ingestible event marker (IEM), a microsensor that becomes activated in gastric fluid, and
an adhesive personal monitor (APM) that detects IEM activation. In this study, the IEM was combined to enteric-
coated mycophenolate sodium (ECMPS). Twenty stable adult kidney transplants received IEM-ECMPS for a mean
of 9.2 weeks totaling 1227 cumulative days.
Results. Eight patients prematurely discontinued treatment due to ECMPS gastrointestinal symptoms (n=2), skin
intolerance to APM (n=2), and insufficient system usability (n=4). Rash or erythema due to APM was reported in 7
(37%) patients, all during the first month of use. No serious or severe adverse events and no rejection episode were
reported. IEM detection accuracy was 100% over 34 directly observed ingestions; Taking Adherence was 99.4% over a
total of 2824 prescribed IEM-ECMPS ingestions. ISS could detect accurately the ingestion of two IEM-ECMPS
capsules taken at the same time (detection rate of 99.3%, n=2376).
Conclusions. ISS is a promising new technology that provides highly reliable measurements of intake and timing of
intake of drugs that are combined with the IEM.
Keywords: Treatment adherence, Kidney transplantation, Ingestible sensor system, Telemedicine, Enteric-coated
mycophenolate sodium.
(Transplantation 2013;96: 245Y250)
Nonadherence to prescribed medications is an importantissue in the clinical management of kidney transplant
patients (1Y3). It is common in the first months after kidney
transplantation and increases by duration of follow-up (4).
Accurate detection of nonadherence is a challenging but
essential first step that enables further interventions aimed
at improving adherence (5, 6). All adherence measurement
methods used currently in transplant patients are indirect; each
has advantages and disadvantages and all lack accuracy (7).
Therefore, more reliable methods that could provide direct
confirmation of medication use and identify nonadherence
are highly desirable to support transplant patients and health-
care professionals who care for them.
The Ingestible Sensor System (ISS) is a new technol-
ogy that enables direct and accurate measurement of med-
ication adherence and the capture of medication intake
dynamics via the ingestion of microsensors that can ac-
company or be incorporated into oral dose forms of active
pharmaceuticals. This device has been approved for use in
European Union (CE-mark) and in the United States (Food
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and Drug Administration clearance). The ISS technology is
composed of the ingestible event marker (IEM), a micro-
sensor that becomes activated after ingestion, and the ad-
hesive personal monitor (APM) affixed to the torso that
detects the IEM once activated (Fig. 1). A wireless Bluetooth-
based interface within the APM allows the APM to transmit its
stored data to a smartphone, which in turn sends the data to a
secured, centralized data storage and processing location via
the mobile telephony network. The objective of this pilot
study was to evaluate the detection accuracy, usability, and
safety of ISS combined with enteric-coated mycophenolate
sodium (ECMPS) in kidney transplants.
RESULTS
Twenty patients participated in this 12-week un-
controlled pilot study. Patients were in majority Caucasians
(19 of 20), males (15 of 20), and 51.7T8.8 years old (meanTSD;
range 35Y68) and had a body weight of 81.8T12.7 kg (range,
54.5Y105.4). They were in stable condition after an average of
6.0T5.0 years after renal transplantation (range, 1Y19 years)
and taking ECMPS or mycophenolate mofetil in combination
with cyclosporine (7 patients), tacrolimus (11 patients),
sirolimus (1 patient), or everolimus (1 patient). Three (15%)
patients had a second transplant.
Patients were exposed to ISS for an average of 9.2 weeks
and a total of 1227 cumulative days. Eight (40%) patients
discontinued treatment prematurely: 2 due to skin intoler-
ance to the APM, 2 due to gastrointestinal symptoms shortly
after introduction of ECMPS, and 4 because of insufficient
system usability that included inadequate mobile telephone
service from the network that was used for the study.
Adherence
Positive detection accuracy (PDA) was 100% (95%
confidence interval [CI], 89.7Y100) in the 34 directly ob-
served ingestions (DOI) performed at clinic visits and in
which the contact of the APM to the skin was satisfactory
(as measured by APM impedance G4000 6) (Table 1). Of
the 4136 IEM-ECMPS prescribed ingestions that took place
without direct observation, 2824 (68%) occurred, whereas
APM impedance was documented to be satisfactory (G40006
for a 24-hr period). The difference between prescribed and
detected ingestions (n=1312) is due mostly to instances when
the APM was not worn by the patient, either because patients
waited for several hours between APM weekly replacements or
discontinued APM use a few days before they discontinued
the study or even decided not to wear the APM during vaca-
tion periods while taking IEM-ECMPS. When the APM was
FIGURE 1. Elements of the ingestible sensor system.
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in place, abnormal impedance was detected in only 16 days
(1.4%) out of a total of 1181 days of use, often after the
recommended period of APM wear (98 days).
Overall adherence to the number of pills ingested ev-
ery day relative to the number of pills prescribed (Taking
Adherence) was 99.4% (95% CI, 99.0Y99.6). In several of the
17 events of missed Taking Adherence, the cause may have
been related to a missed IEM detection, as patients reported
having taken the drug during the period where no detection
occurred. The detection rate of daily medication ingestion
was 99.3% (95% CI, 98.9Y99.6; n=2376) in patients who
took two IEM-ECMPS capsules BID and 100% (95% CI,
99.2Y100; n=448) in those who took one IEM-ECMPS
capsule BID, demonstrating the system’s ability to detect
two IEMs taken at the same time. Adherence to the time
of ingestion (Timing Adherence) was 84.5% (95% CI,
83.1Y85.8) with some day-to-day variations (Fig. 2) but no
significant change over time: Timing Adherence was 85.5%,
82.6%, and 85.2% over the first, second, and third months,
respectively (Table 1). Timing Adherence was lower during
mornings than evenings (82.7% vs. 86.3%; P=0.0109). Mean
deviation from the time window preset for drug intake was
42T50 min (median, 20 min; range, 0.1Y180).
Individual adherence behavior is illustrated in Figure 3,
which shows day-to-day variability in Timing Adherence,
while Taking Adherence remains high. In this case, the daily
APM-to-phone connectivity interval was frequently longer
than 30 min, indicating that this patient was not carrying
the smartphone permanently near the APM. This caused no
detrimental effect on ISS performance, as data that are col-
lected by the APM remain stored on the APM until the APM
returns within Bluetooth range of the smartphone. From the
data that were logged by the ISS, it appears that the patient
took an ‘‘APM holiday’’ between study days 42 and 49.
All patients received at least one automated short
message service (SMS) reminder message in case APM had
not been replaced after 7 days and 15 patients received 10
reminders or more during the entire study period. SMS re-
minders for low adherence to timing of ingestion were sent
to 8 of the 13 patients who entered the weeks 8 to 12 study
period, 2 of whom received more than five messages.
Safety
No serious or severe adverse events and no rejection
episode were reported. Two patients discontinued medica-
tion because of ECMPS-related gastrointestinal symptoms
(diarrhea) shortly after having started ECMPS, one of which
occurred after ECMPS during the run-in period but before
using IEM-ECMPS. Seven patients experienced skin re-
actions to the APM, but in only 2 (10%) did skin intolerance
(rash) lead to discontinuation of the system use, respectively,
TABLE 1. Summary of ISS PDA and patient’s adherence
IEM detected/IEM
prescribed (%) 95% CI
PDA 34/34 (100) 89.7Y100
Taking Adherence
Overall 2807/2824 (99.4) 99.0Y99.6
AM intake 1405/1412 (99.5) 99.0Y99.8
PM intake 1402/1412 (99.3) 98.7Y99.7
Two capsules BID 2359/2376 (99.3) 98.9Y99.6
One capsule BID 448/448 (100.0) 99.2Y100.0
Timing Adherence
Overall 2386/2824 (84.5) 83.1Y85.8
AM intake 1168/1412 (82.7)a 80.6Y84.7
PM intake 1218/1412 (86.3)a 84.4Y88.0
Month 1 928/1086 (85.5)b 83.2Y87.5
Month 2 727/880 (82.6)b 79.9Y85.1
Month 3 731/858 (85.2)b 82.6Y87.5
Observations for periods of APM impedance G4000 6 for 24-hr
periods.
a P=0.0109 (W2 test, AM vs. PM).
b P=0.0865 (M1 vs. M2), P=0.1428 (M2 vs. M3), and P=0.8755 (M1 vs.
M3) (W2 test).
FIGURE 2. Mean timing adherence over time (periods of APM impedance G4000 6).
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after 2 and 36 days. The other five cases of skin reaction were
mild and did not preclude the continuous use of the APM for
the 12-week study duration and successful study completion.
DISCUSSION
This is the first study of the use of ISS, a novel tech-
nology that uses the fixed combination of the IEM with an
immunosuppressant to assess directly daily medication in-
gestion in transplantation. The system demonstrated very
high drug intake detection accuracy during DOIs and the
ability to detect two IEMs taken at the same time, with a
consistent performance over 12 weeks of continuous use.
The uniqueness of this technology is in the physical com-
bination of the IEM with the drug, allowing direct confir-
mation not only of the time of ingestion but also the type,
dose, and number of medications being ingested.
The need for a sensor applied to the skin (the APM)
may be considered as a limitation of the technology. How-
ever, the combination of the IEM and the APM provides
benefits such as allowing for an ultra-low-power highly
miniaturized ingestible sensor. Moreover, it ensures security
in the data transmission, because the IEM’s modulated
current can only be detected for a short period of time and
only with the attachment of the APM sensor to the skin. The
continuous APM contact to the skin can be monitored in
real time by patients and caregivers and, if unsatisfactory,
can be acted upon. Issues with system usability led to dis-
continuation in 20% of patients and were related to the use
of U.S. mobile phones using the CDMA technology that led
to inconsistent mobile network access in Switzerland. This
issue will be resolved by using cell phones that are set to the
mobile network of the patient’s country and checking the
quality of mobile network access at the patient’s home be-
fore prescribing the system. Skin tolerability was a signifi-
cant limitation to the use of the system in about 10% of the
patients but seems to be related to individual sensitivity to
adhesives because cases did not increase over time. Work is
in progress to use alternative APM adhesives with improved
skin tolerability. Patient motivation is also a factor, because
the intent of the ISS is to facilitate a dialogue between the
patient and the medical team regarding treatment adherence
based on an objective assessment of medication intake.
The study was not designed to address the acceptance
of the ISS technology across different transplant patient
populations and subgroups, particularly in relation to their
familiarity with electronic technologies. Although the study
tested the technical feasibility of automated SMS reminders
as a means of providing feedback on medication use, the
study was not designed to modify patient behavior based on
these reminders. No systematic intervention by transplant
clinicians was planned; therefore, no behavioral change was
anticipated.
The ISS technology creates new potential for continual
assessment of medication taking in general and to immuno-
suppressants in transplant patients in particular. However,
further studies will be needed to evaluate patient acceptance
FIGURE 3. Representative example of an individual patient adherence profile and system functionality records. D, day;
h, hour. *For APM activation, each dot represents an APM continuously active for 24 hr. The absence of a dot between days 42
and 49 indicates that the patient was not wearing the patch during this period. **PhoneYserver connection reports the
longest time interval between two connections of the smartphone with the server on each day. For this patient, this time
varied between 30 min and 24 hr, indicating difficulties with mobile network access. †PatchYphone connection reports the
longest time interval between two connections of the APM with the smartphone on each day. This time interval varied also
between 30 min and 24 hr, indicating that the smartphone was not carried permanently by the patient in proximity of the
APM. However, because the data were stored on the APM, the APM data were still communicated to the smartphone and
then to the server at least once a day. ‡Detection of daily medication ingestion was 100% during the entire study period.
§Adherence to the prescribed time of intake fluctuated between 100%, 50% (one of the two daily intakes was not on time),
and 0% (time missed for both daily intakes). ¶Dosing interval was the time between morning and evening intakes and
oscillated around 12 hr, indicating the absence of major time deviation from the prescribed schedule for medication taking.
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for the technology, its suitability to support interventions to
improve medication taking, and the best situations in which
this technology will provide optimal value, such as treatment
adherence training early after transplantation, or supporting
patients who have nonadherent behavior.
MATERIALS AND METHODS
Patients
Twenty kidney transplant recipients were screened and enrolled in this
pilot study between May and August 2011 at five study sites in Switzerland
(ClinicalTrials.gov identifier NCT01320358). To be eligible, patients aged
18 years or older had to be in stable condition at least 6 months after trans-
plantation and be taking a stable prescription of immunosuppressive therapy
that included ECMPS or mycophenolate mofetil. Before enrollment, patients
had to be able to read and to understand the instructions for use of ISS and
to sign a written informed consent form.
Ingestible Sensor System
The ISS developed by Proteus Digital Health (Redwood City, CA) is a
device that directly confirms medication ingestion events and monitors
treatment adherence as well as several physiologic parameters of wellness
such as heart rate, body position, and physical activity (Fig. 1).
The IEM is a tiny device (1.01.00.45 mm) that is composed of an
integrated circuit coated with thin layers of minerals and metals that rests in
the center of an edible, cellulose-based 5 mm disc. Within a few minutes
after ingestion, the sensor uses the electrolytes in the stomach (pH inde-
pendent) to power a biogalvanic battery formed by thin layers (~10 Km) of
magnesium and copper deposited on the IEM’s surface. The ensuing cur-
rent is modulated by the IEM’s microprocessor and creates an electric field
that propagates through the body tissues to the skin surface. The modulated
current is detected, decoded, recorded, and date and time stamped by the
APM, which acts as a receiver. The IEM communicates its identifier for a
finite period of time of approximately 5 to 10 min and can be detected by an
APM only when the APM is adherent to the subject’s skin, thus providing
personal privacy for data recording. This mimics the process whereby bio-
electric signals from cardiomyocytes reach the electrodes of an electrocar-
diogram on the surface of the body. The IEM’s current is less than that of
a human heartbeat, and each sensor’s identifier is unique. This makes it
possible to differentiate multiple IEMs from one another when they are
ingested at the same time. The IEM becomes inactive subsequently and is
excreted in the feces. The extractable amount of copper and magnesium
that can be absorbed by the intestine from a single sensor is very small
compared with their daily allowable amounts for human consumption of
0.3% (7.7 ng) and 0.003% (9.8 ng), respectively. In this study, the IEM
was combined with ECMPS 360 mg tablets by means of an overencapsula-
tion carrier. The IEM-ECMPS combination product was manufactured
according to Good Manufacturing Practices by Novartis Pharma (Basel,
Switzerland).
The APM is a wearable, unmedicated, battery-powered, adhesive-backed
device measuring 11.45.41.3 cm containing electronic sensors capable of
detecting the ingestion of the IEM and of measuring physiologic parame-
ters. Contact of the APM to the skin is made by three conductive gel elec-
trodes. Adequate quality of the APM skin contact, measured every 20 min,
is defined by impedance values lower than 4000 6. The APM may be worn
continuously for 7 days during all activities, including exercising, swim-
ming, and bathing, and is then replaced. APM replacement, including ac-
tivation, and Bluetooth pairing of the new one to its dedicated smartphone
takes approximately 5 min. Each APM carries a unique serial number that is
logged by the system so that APM replacements can be monitored. Every
30 min, the wireless Bluetooth-based interface within the APM is activated
to transmit its stored encrypted data in a secured manner to its designated
smartphone. The data transmitted by the APM include the IEM information,
the APM serial number, impedance, and battery level and the physiologic
parameters. In turn, the smartphone sends the data to a secured, centralized
data storage and processing location via the mobile telephony network using
industry-standard encryption such as the one used by banks. Processed data
are then relayed to the patient and a physician designated by the patient via
SMS messages, smartphone displays, and/or Web site pages. In case of com-
munication difficulties, the data remain stored in the APM and can be
downloaded directly from the APM at a later time whenever necessary. To
maintain privacy, data collection, and all data transmissions and displays,
occur in a secure manner. No personally identifiable information is stored on
the APM or otherwise transmitted between the APM and phone or the phone
and the data center. The use of the ISS has been shown to be safe in patients
wearing implantable devices such as pacemakers or defibrillators.
Study Design
This is an open-label single-arm exploratory study of 12 weeks’ duration.
Main study endpoints were IEM detection accuracy when compared to
DOI, Taking Adherence, and Timing Adherence, the latter being defined by
IEM detection within the timeT1 hr window preset by the patient for
morning and evening drug intakes.
At the first visit, patients were trained to use the ISS technology and the
mobile phone that was provided for the study and to replace the APM every
week. Their treatment was then converted from regular ECMPS to the
equivalent number of IEM-ECMPS 360 mg capsules. Patients who were
receiving mycophenolate mofetil had their therapy converted and stabilized
to the equivalent dose of ECMPS during a 2-week run-in period before
using IEM-ECMPS.
DOI took place during clinic visits on day 1 and weeks 1, 4, 8, and 12,
and each ingestion was observed by the study nurse who recorded the date
and time of ingestion. In the event that a patient had already taken the
regular morning dose of IEM-ECMPS, an IEM-placebo combination cap-
sule of equal size was substituted to perform the DOI. Of the 34 DOI,
8 consisted of IEM-placebo ingestions; detection accuracy was 100% for
both the IEM-ECMPS and IEM-placebo ingestions. Between visits, the in-
take of IEM-ECMPS was assessed continuously by the ISS for the duration
of the study. During the entire study duration, patients received automated
SMS messages to remind them of changing their APM if it had been worn
for more than 7 days or when APM battery depletion was detected. In ad-
dition, from weeks 8 to 12, patients received automated adherence SMS
reminders if their average timing adherence had been less than 84%, or one
missed intake, over the previous 72 hr. During the weeks 8 to 12 period,
patients had access also to graphical displays of their adherence records on
the smartphone. Study site nurses had access to their patients’ full adher-
ence data on the secure study Web site and received also a weekly E-mail
report of individual patient’s adherence records over the elapsed week,
which they could share with the patient.
Definition of Endpoints and Statistical Methods
All statistical analyses were descriptive. All analyses of adherence were
conducted for periods when APMs had satisfactory skin contact (imped-
ance G4000 6) because APM can detect IEM ingestion only when it is
properly adherent to the body. For DOI, an impedance less than 4000 6 had
to be confirmed before and after the time of DOI recorded by the nurse. For
daily adherence assessments, all daily impedance measurements by the APM
had to be less than 4000 6. Endpoints were defined as follows:
& PDA=proportion of IEM detected relative to the number of DOI.
& Taking Adherence=number of IEM detected divided by the number of
IEM-ECMPS prescribed during the study period.
& Timing Adherence=number of IEM detected within the time window
preset by the patient divided by the number of IEM-ECMPS capsules
prescribed. A 2-hr time window for drug ingestion was defined at time of
inclusion by each patient for morning and evening intakes; this time
window could not be modified thereafter. The magnitude of time de-
viations from the target window was also reported for the subset of in-
gestions occurring outside that window.
The safety analysis included all patients who received at least one dose of
IEM-ECMPS.
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Study Oversight
This study was conducted in accordance with the International Confer-
ence on Harmonisation Tripartite Guidelines for Good Clinical Practice,
with applicable local regulations, and with the ethical principles laid down
in the Declaration of Helsinki. The institutional review boards of partici-
pating centers approved the study protocol (EKBB 285/10). All patients
provided written informed consent. Novartis, the study sponsor, was re-
sponsible for the study conduct, data collection and statistical analysis;
Proteus was responsible for managing the ISS data flow. The data stored on
the Proteus server was secure and anonymized and patients were identi-
fied only by their study number. Data was then transferred to Novartis and
matched with the study database before the statistical analyses that were
also conducted by Novartis. The study was cofunded by Novartis and Proteus.
The authors had full access to the data, wrote this article, and take responsi-
bility for the accuracy of the reported analysis.
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